Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc. (Nasdaq:BCRX).  The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

The MACD for BCRX currently indicates a strong bearish signal for two reasons.  First, the MACD is below the signal line, a 9-day moving average.  Second, the MACD is below the critical level of zero, which implies that the underlying moving averages are trending lower.

BioCryst Pharmaceuticals Inc. (BCRX) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases.  BCRX integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design.  The Company's product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP).  An oral formulation of the compound is in a phase IIb trial for patients with Cutaneous T-cell Lymphoma (CTCL).  Additionally, forodesine HCl is being studied in a phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL).  The Company's another drug candidate, peramivir, is an inhibitor of influenza neuraminidase.

Message Board Search for BCRX: http://www.boardcentral.com/boards/BCRX

In the report, the analyst notes:

"For the three months ended March 31, 2010, total revenues increased to $26.1 million compared to $4.4 million for the three months ended March 31, 2009.  This $21.7 million increase was driven primarily by the recognition of a $7.0 million milestone payment from the Company's partner, Shionogi & Co. Ltd.

"BCRX recently announced it is initiating a phase II study of BCX4208 alone and in combination with allopurinol in patients with gout.  BCRX recently reported positive results from part one of its phase II monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional phase II trial of BCX4208."